The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Tue, 26th Oct 2021 19:06

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Yellow Cake PLC - Jersey-based investor in uranium - Plans to raise USD150 million through placing. Will fund purchase of three millions pounds of physical uranium. "The long term outlook for the uranium price remains strong, driven by the more positive demand outlook and on-going supply constraints, causing the supply deficit to grow every year. We continue to seek further opportunities for value accretive opportunistic uranium purchases at an attractive price," Chief Executive Officer Andre Liebenberg says.

----------

Mercia Asset Management PLC - West Midlands-based asset manager - Completes GBP1.8 million investment into new portfolio company Forensic Analytics Ltd, alongside GBP2.7 million backing by Mercia managed Northern VCTs. "Following this investment, Mercia holds an 8.9% fully diluted direct equity stake in Forensic Analytics, with the Northern VCTs holding a further 13.9% fully diluted equity stake," Mercia says.

----------

Tern PLC - investor focused on the internet of things - Says "significant business momentum" continues across principal portfolio firms. Device Authority Ltd investee launches KeyScaler Edge offering to address IoT security challenges. "In addition to new customer wins and repeat orders, Device Authority have recently entered into further distribution partnerships, including with Trusted Objects, a leading independent player in cybersecurity technologies for embedded systems and cloud device management platforms, and with Titan Automotive Solutions, a leading provider of car connectivity solutions with a global presence," Tern says. Tern owns 57% of Device Authority. Virtual reality focused investee FVRVS Ltd, meanwhile, wins deal with company previously using a competitor's product. InVMA Ltd sees "strong sales growth", while Wyld Networks AB "continued to make further significant progress following its IPO on the NASDAQ First North Growth Market in Stockholm".

----------

Path Investments PLC - Bingley, England-based natural resources investment company - Says longstop date for DG Innovate Ltd buy extended to December 31. "Path and its advisers continue to progress the proposed transaction," company says.

----------

Caerus Mineral Resources PLC - London-based exploration & resource development company - Says trenching of stockpiles at Troulli project finds "very high-grade visible copper mineralisation". Copper grades are "highly significant", based on semi-quantitative XRF analysis. "Samples have been collected and are ready for dispatch to the assay laboratory," Caerus says. Duplicate samples also sent to partner Jubilee Metals Group PLC for testwork.

----------

Petra Diamonds Ltd - London-based diamond miner - Says revenue in first quarter ended September 30 improves year-on-year to USD114.9 million from USD77.7 million a year earlier. Says output falls annually to 861,991 carats from 974,346 carats.

----------

IMC Exploration Group PLC - Dublin-based exploration company focused on Ireland - Says drillhole 21-3850-01 at West Avoca encounters "four zones of massive and semi massive sulphide mineralisation". Says 18.7 metre interval or zinc, lead and silver mineralisation found. "IMC plans that the drill programme will allow an independent resource calculation to be undertaken in addition to that already in place for the spoils' and tailings' project," IMC adds.

----------

Angus Energy PLC - oil & gas development company - Shares revised competent persons report at Saltfleetby gas field. Says conservative estimate, or P90, of future cashflows to Angus stands at GBP31.7 million. Mid-case, or P50, has it at GBP55.9 million. Angus adds: "In summary the report estimates production giving rise to gross field revenues, before costs on a mid-case basis of GBP230 million (previously GBP141 million) of which Angus's share is 51%."

----------

Oxford Metrics PLC - software company servicing infrastructure, life sciences, entertainment and engineering markets - Says motion measurement unit Vicon wins deal with volumetric content and virtual production firm Dimension Studios. "Vicon's tracking, of both rigid and full body subjects, will be used alongside Dimension Studio's volumetric and real-time development capabilities by leading visual effects company DNEG for several high-profile virtual production projects - including a major motion picture and a 10-hour TV series," Oxford Metrics says.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says third quarter sales "strong" at USD964,000. "Importantly, both the September and June 2021 quarters combined have delivered a record USD2.24 million in cash receipts from customers over the 6-month period, with increasing month on month sales generated from new key markets, such as the UK and Ireland," MGC adds.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Teams with University College London to research generation of immune cells from induced pluripotent stem cells as a potential cancer therapy. ReNeuron will provide UCL with the stem cells. Company adds: "Induced pluripotent stem cells can differentiate into any cell type found in the body, but unlike most iPSCs, ReNeuron's proprietary CTX-iPSCs carry the conditional immortalisation system incorporated into CTX. ReNeuron's CTX derived iPSC's are available as clinical grade material potentially allowing faster development of arising therapeutics and the company believes that its conditional immortalisation technology could allow the company to manufacture cost efficiently at scale to treat large numbers of patients providing 'off the shelf' cell therapies."

----------

Omni Egis PLC - debt financing solutions provider for small to medium-sized businesses - Says AQSE listing "not commercial for the company to raise funds at the current share price". Notes market capitalisation currently below liquid resources. Convenes general meeting on November 18 to vote on AQSE withdrawal.

----------

CATCo Reinsurance Opportunities Fund Ltd - invests in catastrophe reinsurance risks - Receives "substantial level of investor support" for Markel CATCo Investment Management Ltd-funded buyout. Markel is CATCo's manager.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.